Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/29/2010WO2009143246A3 Arylsulfonamide compounds, compositions and methods of use
04/29/2010WO2009141541A3 Use of kif13a and ap-1 inhibitors for inhibiting melanogenesis
04/29/2010WO2009138507A3 Anti-cancer combination therapy
04/29/2010WO2009131553A3 Methods of altering bone growth by administration of sost or wise antagonist or agonist
04/29/2010WO2009117277A3 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
04/29/2010WO2009113741A3 Combination of a carbostyril and carnitine
04/29/2010WO2009111057A4 Fulvestrant formulations
04/29/2010WO2009108077A3 Pharmaceutical composition for poorly soluble drugs
04/29/2010WO2009073147A3 Process for preparing bis(thiohydrazide amides)
04/29/2010WO2009037319A3 Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine
04/29/2010WO2009026446A8 Hdac inhibitors
04/29/2010WO2009024763A3 Combination therapy
04/29/2010WO2009021991A9 Use of r(+)-alpha-lipoic acid for cryptogenic neuropathy
04/29/2010WO2009018195A3 Fly control method
04/29/2010WO2009011449A3 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
04/29/2010WO2008092928A9 NOVEL ß-LACTAM ANTIBIOTICS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF
04/29/2010WO2005094236A9 Activation of hypoxia-inducible gene expression
04/29/2010US20100106244 3-Deazaadenosine prevents atherosclerosis and graft vasculopathy
04/29/2010US20100105953 Human Adam-10 Inhibitors
04/29/2010US20100105946 Hydrolytically Degradable Carbamate Derivatives of Poly(Ethylene Glycol)
04/29/2010US20100105922 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
04/29/2010US20100105915 Chemokine receptor binding heterocyclic compounds
04/29/2010US20100105896 Pharmaceutical compounds
04/29/2010US20100105894 Cyclopropane compounds and pharmaceutical use thereof
04/29/2010US20100105781 Abuse resistant lysine amphetamine compounds
04/29/2010US20100105780 Colchicine compositions and methods
04/29/2010US20100105779 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
04/29/2010US20100105778 treating neuropathic pain with milnacipran or salt
04/29/2010US20100105777 Amide or thioamide derivatives and their use in the treatment of pain
04/29/2010US20100105776 Use of malachite green in the form of drug for treating malignant neoplasms
04/29/2010US20100105775 Amino acid salts of prostaglandins
04/29/2010US20100105774 Antidepressant
04/29/2010US20100105773 Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
04/29/2010US20100105772 Use of novel lipid mediators to inhibit angiogenesis
04/29/2010US20100105771 Amino acid salts of prostaglandins
04/29/2010US20100105770 Therapeutic delivery of carbon monoxide
04/29/2010US20100105769 pharmaceutical composition containing daurinol for the prevention and treatment of cancers
04/29/2010US20100105767 Compounds, compositions and methods
04/29/2010US20100105766 Composition for inhibition or prevention of bone density reduction
04/29/2010US20100105765 Combination Therapy For Effecting Weight Loss And Treating Obesity
04/29/2010US20100105764 Use
04/29/2010US20100105763 Pharmaceutical composition, health food composition and inos inhibitors, containing theopederin derivatives
04/29/2010US20100105762 Therapeutic agent for periodontal disease and alveolar bone loss due to surgery
04/29/2010US20100105761 Treatment of pain through expression of opioid receptors
04/29/2010US20100105760 Treatment of Apolipoprotein-A1 Related Diseases by Inhibition of Natural Antisense Transcript to Apolipoprotein-A1
04/29/2010US20100105759 H19 silencing nucleic acid agents for treating rheumatoid arthritis
04/29/2010US20100105758 Use of an adenosine antagonist
04/29/2010US20100105757 Treatment and inhibition of disease conditions using flexible heteroarotinoids
04/29/2010US20100105756 Method of Treating Down Syndrome
04/29/2010US20100105755 Substituted benzamide modulators of dopamine receptor
04/29/2010US20100105754 5-(4phenyl)prolinamide for treatment of epilepsy
04/29/2010US20100105753 Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof
04/29/2010US20100105751 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
04/29/2010US20100105750 Stable metronidazole gel formulations
04/29/2010US20100105749 Chemical compounds, pharmaceutical compositions and methods
04/29/2010US20100105748 Methods and compositions for treatment of drug addiction
04/29/2010US20100105747 Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
04/29/2010US20100105746 Method for treating metabolic diseases
04/29/2010US20100105745 Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
04/29/2010US20100105744 Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof
04/29/2010US20100105743 Pharmaceutical compositions and methods for stabilizing the same
04/29/2010US20100105741 Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss
04/29/2010US20100105740 vanilloid receptor antagonists such as 1-[4-(2-hydroxyethoxy)-2-bromo-5-methoxybenzyl]-3-[4-(trifluoromethyl)-benzyl]urea, useful for the treatment of neuropathic pain, urogenital disorders, hemorrhoids, inflammation, post-operative pain, respiratory and gastrointerstinal disorders
04/29/2010US20100105739 Modulators of atp-binding cassette transporters
04/29/2010US20100105738 Extended release formulations of a proton pump inhibitor
04/29/2010US20100105737 PYRIDINE DERIVATIVES SUBSTITUTED WITH HETEROCYCLIC RING AND gamma-GLUTAMYLAMINO GROUP, AND ANTIFUNGAL AGENTS CONTAINING SAME
04/29/2010US20100105736 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
04/29/2010US20100105735 Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain
04/29/2010US20100105734 Treatment xerophthalmia with norketotifen
04/29/2010US20100105733 Treatment of vasomotor symptoms with selective estrogen receptor modulators
04/29/2010US20100105732 Piperidine gpcr agonists
04/29/2010US20100105731 Novel benzamidine compound
04/29/2010US20100105730 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
04/29/2010US20100105729 Aryl-substituted heterocyclic pde4 inhibitors as anti-inflammatory agents
04/29/2010US20100105728 Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
04/29/2010US20100105727 Novel benzamide derivatives and process for the prepartion thereof
04/29/2010US20100105726 Imidazole derivatives that induce apoptosis and their therapeutic uses
04/29/2010US20100105725 Antidiabetic bicyclic compounds
04/29/2010US20100105724 Crystalline and amorphous forms of palonosetron hydrochloride
04/29/2010US20100105723 5-PHENYL-6-PYRIDIN-4-YL-1,3-DIHYDRO-2H-IMIDAZO[4,5-b]PYRIDIN-2-ONE DERIVATIVES USEFUL AS A2B ADENOSINE RECEPTOR ANTAGONISTS
04/29/2010US20100105722 Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators
04/29/2010US20100105721 IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS
04/29/2010US20100105720 Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
04/29/2010US20100105719 Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
04/29/2010US20100105718 Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists
04/29/2010US20100105717 Tacrolimus for improved treatment of transplant patients
04/29/2010US20100105716 Camkk(beta) as a target for treating obesity
04/29/2010US20100105715 Polymer conjugates of opioid antagonists
04/29/2010US20100105714 Furanone Compounds and Methods of Making and Using The Same
04/29/2010US20100105713 GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
04/29/2010US20100105712 Chemical compounds
04/29/2010US20100105711 Organic Compounds
04/29/2010US20100105710 Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
04/29/2010US20100105709 6-Butyl-2-methoxy-5-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-3-phenylpyrimidin-4(3H)-one; for hypertension, cardiac disease, arteriosclerosis, kidney disease, stroke, dyslipidemia, obesity, diabetes, nonalcoholic steatohepatitis, dementia and/or Alzheimer's disease in a mammal
04/29/2010US20100105708 Pyrrolopyrimidines for pharmaceutical compositions
04/29/2010US20100105707 Method of treating or preventing oxidative stress-related disease
04/29/2010US20100105706 Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
04/29/2010US20100105705 Purinyl derivatives and their use as potassium channel modulators
04/29/2010US20100105704 7-(3',4'-Dialkoxyphenyl)-[1,2,4]-Triazolo[1,5-A]Pyrimidine Compounds, Process for Preparing Thereof, and Pharmaceutical Composition for Treating or Preventing Asthma, Chronic Obstructive Pulmonary Disease, Arthritis, Atopic Dermatitis, Tumor and Degenerative Brain Diseases Comprising the Same
04/29/2010US20100105703 Synthetic Mimetics Of Host Defense And Uses Thereof